Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will present at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be available online once the conference begins, with a webcast accessible via Viking's website. Viking Therapeutics focuses on developing innovative therapies for metabolic and endocrine disorders, including its lead candidates VK2809 and VK0214, which are in advanced stages of clinical trials.
- None.
- None.
SAN DIEGO, Jan. 3, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference. The conference, which will take place January 10-13, 2022, is being conducted with a virtual format.
Details for this presentation are as follows:
- H.C. Wainwright BioConnect 2022 Conference
Conference Dates: January 10-13, 2022
Presentation Timing: Available online upon start of conference on Monday, January
10, 2022
Format: Virtual conference; webcast available
A webcast of the H.C. Wainwright presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. The webcast will be available on the Viking website once the conference gets underway on January 10, 2022.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's second clinical candidate is VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. The company is also developing a wholly-owned series of novel dual agonists of the GLP-1 and GIP receptors, for the potential treatment of metabolic disorders.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-hc-wainwright-bioconnect-2022-conference-301452500.html
SOURCE Viking Therapeutics, Inc.
FAQ
When is Viking Therapeutics presenting at the H.C. Wainwright BioConnect 2022 Conference?
What is the format of the H.C. Wainwright BioConnect 2022 Conference?
How can I access the webcast for Viking Therapeutics' presentation?
What are the key clinical programs being developed by Viking Therapeutics?
What is the significance of VK2809 in Viking's pipeline?
